Most Read Articles
Pearl Toh, 3 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
6 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 07 Dec 2018
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.
2 days ago
Rates of major bleeding events are similar across cancer patients taking direct oral anticoagulants (DOAC), low-molecular-weight heparin (LMWH) or vitamin K antagonist (VKA), with gastrointestinal bleeding being the most frequent event, a recent study has shown. In addition, DOAC and LMWH recorded higher rates of venous thromboembolism than earlier studies.

CV efficacy, safety of GLP-1 receptor agonists a class effect

Roshini Claire Anthony
15 Jan 2018

The cardiovascular (CV) efficacy and safety of glucagon-like peptide-1 (GLP-1) receptor agonists in type 2 diabetes (T2D) appear to be a class effect, according to a systematic review and meta-analysis of four major GLP-1 CV safety trials.

“Overall, this meta-analysis shows a consistent finding of [CV] safety across all GLP-1 receptor agonist drugs evaluated and suggests that this class of glucose-lowering drugs seems to reduce three-point [major adverse CV events (MACE)], CV mortality, and all-cause mortality, albeit with possible differences between individual drugs reflected in the individual trial results,” said the researchers.

“The capacity of … GLP-1 receptor agonist[s] to reduce MACE in patients with T2D at moderate-to-high CV risk and to do so without detrimental effects on other safety parameters represents a major therapeutic advance,” they said.

Using data from the ELIXA*, LEADER**, SUSTAIN 6***, and EXSCEL# trials, researchers assessed the CV efficacy and safety of lixisenatide (≤20 µg QD), liraglutide (1.8 mg QD), semaglutide (0.5 or 1.0 mg QW), and extended-release exenatide (2 mg QW) vs placebo in 33,457 adult patients with T2D.

Patients on GLP-1 receptor agonists demonstrated a significant reduction in the relative risk of three-point MACE namely CV mortality, nonfatal myocardial infarction (MI), and nonfatal stroke compared with those on placebo (hazard ratio [HR], 0.90, 95 percent confidence interval [CI], 0.82–0.99; p=0.033). [Lancet Diabetes Endocrinol 2017;doi:10.1016/S2213-8587(17)30412-6; IDF 2017, abstract 293]

The risk reduction remained significant with regards to CV mortality (HR, 0.87, 95 percent CI, 0.79–0.96; p=0.007) and all-cause mortality (HR, 0.88, 95 percent CI, 0.81–0.95; p=0.002), while there was no impact on fatal or nonfatal MI (HR, 0.94; p=0.18), fatal or nonfatal stroke (HR, 0.87; p=0.052), or hospitalization for unstable angina or heart failure (HR, 1.09; p=0.39 and HR, 0.93; p=0.20, respectively).

“[The study findings] … lend support to the hypothesis that the CV effects of GLP-1 receptor agonists might be mediated via antiatherogenic mechanisms that decrease CV risk over time. These mechanisms might include direct and indirect effects of GLP-1 receptor agonists on common CV risk factors, anti-inflammatory pathways, cardiac output, ischaemic conditioning, and endothelial function,” said the researchers.

They acknowledged that use of aggregate as opposed to patient-level data limited the ability to examine other subgroups, while the short follow-up period (2–4 years) did not allow for discernment of potential outcomes with longer term use.

 

Promising CV safety

There was also little difference between patients on GLP-1 receptor agonists and placebo in terms of the safety outcomes analysed, ie, the incidence of severe hypoglycaemia (odds ratio [OR], 0.93; p=0.56), pancreatitis (OR, 0.90; p=0.54), or pancreatic cancer (OR, 0.83; p=0.70), though there was significant between-trial heterogeneity with regards to pancreatic cancer and severe hypoglycaemia incidence.

According to the researchers, the definitions of severe hypoglycaemia varied slightly between trials as did the management of concomitant antihyperglycaemic treatment, factors that could have potentially affected severe hypoglycaemia rates. The reasons for the discordance in pancreatic cancer incidence is unknown, though the researchers did not rule out a chance finding.

 

Trial heterogeneity suggests a per-patient approach

The findings of these individual trials have been varied, thus raising “important questions about the generalizability of GLP-1 receptor agonist trials to the drug class as a whole”, said the researchers.

“[A]lthough there were differences between individual drugs with respect to their effect on CV outcomes in the separate trials, [o]verall, these data show a favourable risk-benefit profile for GLP-1 receptor agonists,” they said, suggesting that the choice of drug for each patient should be evidence-based and take into consideration factors such as convenience, tolerability, and price.

Professor Simeon Taylor from the University of Maryland School of Medicine, Baltimore, Maryland, US, agreed. “[T]here is considerable inter-individual variation with respect to the magnitude of clinical benefit, suggesting that a personalized medicine strategy might enable physicians to select the best drug for each patient,” he said in a commentary, emphasizing the stronger risk reduction observed with liraglutide and extended-release exenatide on obese compared with non-obese patients. [Lancet Diabetes Endocrinol 2017;doi:10.1016/S2213-8587(17)30413-8]

“Future research will be necessary to clarify how BMI or other clinical criteria should be taken into account when predicting the magnitude of clinical benefit likely to be provided by specific drugs used for the treatment of T2D,” he said.

 

 

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 3 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
6 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 07 Dec 2018
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.
2 days ago
Rates of major bleeding events are similar across cancer patients taking direct oral anticoagulants (DOAC), low-molecular-weight heparin (LMWH) or vitamin K antagonist (VKA), with gastrointestinal bleeding being the most frequent event, a recent study has shown. In addition, DOAC and LMWH recorded higher rates of venous thromboembolism than earlier studies.